Search

Ardelyx Inc

Închisă

SectorSănătate

3.76 0.8

Rezumat

Modificarea prețului

24h

Curent

Minim

3.7199999999999998

Maxim

3.91

Indicatori cheie

By Trading Economics

Venit

21M

-17M

Vânzări

26M

121M

EPS

-0.07

Marjă de profit

-13.833

Angajați

489

EBITDA

20M

-10M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+264.44% upside

Dividende

By Acuity

Următoarele câștiguri

29 oct. 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

-182M

1B

Deschiderea anterioară

2.96

Închiderea anterioară

3.76

Sentimentul știrilor

By Acuity

67%

33%

307 / 340 Clasament în Healthcare

Ardelyx Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

21 aug. 2026, 19:16 UTC

Ardelyx Inc shares are higher today, continuing positive momentum since Thursday. No specific news was identified to explain the price movement.

20 aug. 2026, 20:01 UTC

News

Ardelyx Inc shares are lower amid a securities investigation into its revised IBSRELA revenue guidance, which was cut to $350-$370 million.

19 aug. 2026, 23:01 UTC

Ardelyx Inc. shares are higher in after-market trading, reflecting broader market gains. The stock remains below its 20-day moving average.

18 aug. 2026, 23:06 UTC

Ardelyx Inc. shares are roughly flat in after-market trading. The stock is down significantly compared to its month-ago close and below its 20-day moving average.

17 aug. 2026, 19:26 UTC

News

Ardelyx shares are lower as Levi & Korsinsky investigates potential federal securities law violations amid reduced revenue guidance for IBSRELA.

14 aug. 2026, 23:56 UTC

Ardelyx Inc. shares declined in after-market trading, continuing a broader trend of significant decline over the past month, remaining below the 20-day moving average.

13 aug. 2026, 23:01 UTC

Ardelyx Inc. shares advanced modestly in after-market trading, though they remain significantly below the 20-day moving average and near the one-month range's lower end.

12 aug. 2026, 23:26 UTC

Ardelyx Inc. shares were trading roughly flat in after-market hours. The stock has declined significantly over the past month amid broader market weakness.

11 aug. 2026, 19:56 UTC

Ardelyx Inc's shares are lower today, reflecting a broader decline in the biotechnology sector. Investors monitor macroeconomic factors ahead of the Consumer Price Index report.

10 aug. 2026, 23:56 UTC

Ardelyx Inc shares are higher in after-market trading, despite no specific news driving the move. Recent market conditions include cautious optimism following a jobs report.

7 aug. 2026, 23:31 UTC

News

Ardelyx shares are higher in after-market trading as TD Cowen maintains a Buy rating and lowers the price target to $10.

6 aug. 2026, 23:31 UTC

News
Social Media

Ardelyx Inc. reports Q2 revenue of $118.1 million, missing expectations. Shares decline in after-market trading following revised financial guidance and a net loss of $16.7 million.

3 aug. 2026, 19:16 UTC

Ardelyx Inc. shares are trading roughly flat with no specific news identified. The stock remains below its 20-day moving average.

31 iul. 2026, 19:16 UTC

Ardelyx Inc. shares are lower, reflecting broader market trends amid rising yields and inflationary pressures, particularly after a notable increase in crude oil prices.

30 iul. 2026, 23:51 UTC

Ardelyx Inc. shares are lower in after-market trading, remaining below their 20-day moving average amid broader market weakness.

22 iul. 2026, 19:31 UTC

Ardelyx Inc shares are higher in Wednesday's session, continuing a modest rise since Tuesday's close. The stock remains below its 20-day moving average.

20 iul. 2026, 19:02 UTC

Ardelyx shares are lower today, reflecting broader weakness in the biotechnology sector. The stock has declined since Friday's close with no specific news identified.

Comparație

Modificare preț

Ardelyx Inc Așteptări

Obiectiv de preț

By TipRanks

264.44% sus

Prognoză pe 12 luni

Medie 13.63 USD  264.44%

Maxim 18 USD

Minim 9 USD

În baza a 8 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruArdelyx Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

8 ratings

8

Cumpărare

0

Păstrare

0

Vânzare

Sentiment

By Acuity

307 / 340 Clasament în Sănătate

Sentimentul știrilor

Evidențe de scădere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Ardelyx Inc

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
help-icon Live chat